

Amendments to the Specification

Please enter the attached sequence listing into the record of the application:

Please amend the title of the specification as follows:

Inhibiting vascularization using antibodies to CXCR4 and SDF-1 ~~Vascularization Inhibitors~~

Please amend the paragraph starting on page 15, line 5, as follows:

Also, the amino acid sequence of SDF-1, which is a ligand binding to CXCR4, has already been known. There are two types of SDF-1 differing in the length of amino acid sequence, *i.e.*, SDF-1- α and SDF-1- β . Specifically, the amino acid sequence of human SDF-1- α is set forth in SEQ ID NO: 5 and its base sequence in SEQ ID NO: 6 (base positions 474-740). Human SDF-1- β (~~SEQ ID NO: 9~~) is derived from human SDF-1- α by appending four amino acid residues, Arg-Phe-Lys-Met (SEQ ID NO: 9), to a C-terminus thereof.

Please amend the paragraph starting on page 15, line 15, as follows:

The amino acid sequence of murine SDF-1- α is set forth in SEQ ID NO: 7 and its base sequence in SEQ ID NO: 8 (base positions 82-348). Murine SDF-1- β (~~SEQ ID NO: 10~~) is derived from murine SDF-1- α by appending four amino acid residues, Arg-Leu-Lys-Met (SEQ ID NO: 10), to a C-terminus thereof. For human and murine SDF-1's, the sequence of from the 1st amino acid (Met) to the 21st amino acid (Gly) is a signal sequence.